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SusceptibilityAbstract Background: Neutrophils are able to trap and kill microbes via the release of their DNA
decorated with proteins from granule and histones into the extracellular environment; however, this
mechanism has also emerged as a potential source of auto-antigens and inflammation during the
course of many autoimmune diseases. It has been demonstrated that neutrophils from patients with
rheumatoid arthritis (RA) have a greater propensity to release neutrophil extracellular traps
(NETs). DNAse I, an endonuclease involved in the breakdown of chromatin, has been implicated
in the pathophysiology of autoimmune diseases.
Aim of the work: To investigate the genetic associations of a non-synonymous single nucleotide
polymorphism (SNP) in DNAse I with the risk of RA and its influence on clinical and radiographic
features in an Argentinean population.
Patients and methods: The Q222R A/G DNAse I SNP was studied in 210 RA patients and 206
matched healthy controls. Disease activity score, health assessment questionnaire and the modified
Sharp van der Heijde score were assessed.
Results: The patients’ median age was 56 years (48–64), disease duration 128 months (20–205)
and 86.7% were females. Genotype distribution and G-allele frequency were comparable between
patients and control. There was no significant association of the Q222R A/G genotypes with disease
susceptibility, activity, functional status or radiological score among RA Argentine patients.2AEN),
290 F.M. Aranda et al.Conclusions: No significant genetic association was found between the carriage of the DNAse I
Q222R G-allele and the risk of RA nor was there any association with the disease activity, func-
tional capacity or severity in an Argentine patient cohort.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neutrophils can release their DNA as extracellular fibers or
neutrophil extracellular traps (NETs) painted with proteins
from all granule groups and histones to confine microbes, kill
them and control infections [1].
NETosis can also be performed in the absence of microbial
stimuli, with an appropriately pro-inflammatory milieu [2,3].
Moreover, NETosis has also emerged as a potential source
of auto-antigens that perpetuate inflammation, which has
made this process a focus of attention in the development
and course of many inflammatory and autoimmune diseases
[1,4,5]. It has been demonstrated that neutrophils from
patients with rheumatoid arthritis (RA) have a greater propen-
sity to release NETs and their serum and synovial fluid can
stimulate NET formation in control neutrophils, which is asso-
ciated with the levels of autoantibodies (mainly citrullinated
proteins and rheumatoid factor) and with systemic markers
of inflammation [6–8]. NETosis in RA patients can stimulate
pro-inflammatory gene expression in fibroblast-like synovio-
cytes showing a clear relationship between NETs and joint
destruction [6].
Defects in apoptotic or necrotic debris or NET clearance
are strongly associated with autoimmune diseases such as sys-
temic lupus erythematosus (SLE) [9]. DNAse I, an endonucle-
ase involved in the breakdown of chromatin, has been
implicated in the pathophysiology of this autoimmune disease
[10,11]. Indeed, DNAse I knockout mice develop a lupus-like
syndrome [12]. Human DNAse I is genetically polymorphic
and is controlled by six codominant alleles. The G allele of
the single nucleotide polymorphism (SNP) Q222R
(rs1053874), that codes for a DNAse I with reduced enzyme
activity, was reported to be associated with SLE susceptibility
in certain populations [13,14], and it was linked to the develop-
ment of anti-RNP and anti-dsDNA antibodies [15]. However,
not all reports in the literature found such associations.
As the distribution of the Q222R DNAse I SNP is strictly
related to ethnicity and there is no enough evidence regarding
its association with susceptibility to and/or the course of RA
disease, we decided to investigate the relationship of this
SNP with susceptibility to RA and with clinical and radio-
graphic features of RA patients in an Argentinean population.2. Patients and methods
A non-family-based case-control multicenter study was
designed. A total of 416 subjects were recruited for this study
including 210 consecutive RA patients who fulfilled the revised
classification criteria of the American College of Rheumatol-
ogy (ACR) 1987 for RA [16] and an age and gender matched
control group that consisted of 206 subjects from the general
population, strictly unrelated, without personal history ofchronic inflammatory or autoimmunity diseases. The median
age of the RA group was 56 years (48–63) and 86.7% of them
were female. The median age of the control group was 51 years
(44–61) and 82.5% of them were female (p= 0.39 and
p= 0.3, respectively). All subjects were of Argentine descent
and had the same ethno-geographic and social origin. The
Argentinean population is the result of genetic admixture pro-
cesses involving three continental contributors: Native Ameri-
cans, Western Africans and Europeans (mainly Spaniards and
Italians), although the African component detected in different
studies was very low (less than 4%) [17,18]. We selected a rep-
resentative sample of the admixed urban Argentinean popula-
tion. The study was approved by the ethics committee of the
respective medical centers and was performed according to
the principles of the Declaration of Helsinki. Informed consent
was obtained from all of the participants.
The following data were collected for all RA study partici-
pants: sex, age, disease duration, extra articular manifestations
and presence of Rheumatoid Factor (RF). Disease activity was
assessed using Disease Activity Score 28 (DAS28) [19], and
functional capacity was assessed using the Health Assessment
Questionnaire Argentinean version (HAQ-A) [20]. Hand and
feet X-rays were evaluated by three blinded observers using
the modified Sharp van der Heijde score [21] (ICC = 0.92).
DAS 28, HAQ-A and the modified Sharp van der Heijde
(SvH) score were transformed into categorical variables,
according to clinical criteria, as follows: DAS28 and HAQ
were categorized according to established cut-offs, into three
categories (<2.6, 2.61–3.2 and >3.2; and <1, 1–2 and >2,
respectively) and SvH modified score was categorized accord-
ing to quartile values (<58, 59–119, 120–162 and >162) as
there is no established cut-off for this variable.
Venous blood was drawn without stasis from 416 subjects
and collected in tubes containing EDTA. Subsequently, geno-
mic DNA was isolated from 200 ll of whole blood using a
QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA).
2.1. Genotype analysis
Q222R SNP (+2373A? G) was analyzed via polymerase
chain reaction followed by restriction fragment length poly-
morphism (PCR-RLFP). Primers for the specific amplification
of the DNA fragment encompassing the SNP were designed on
the basis of the nucleotide sequence of the human DNASEI
(GeneBank accession No. D83195). PCR amplification was
performed in a 50 ll reaction mixture using 10 ng of DNA.
The reaction mixture contained 1X buffer (10 mM Tris–HCl,
pH 8.8, 50 mMKCl, 0.08% (v/v), Nonidet P40), 3 mMMgCl2,
0.2 mM dNTPs, 1 lM of each primer and 1.25 U of Taq DNA
polymerase (Thermo Scientific, Waltham, Massachusetts,
USA). PCR was performed with a protocol consisting of initial
denaturation at 94 C for 5 min, followed by 35 cycles with
denaturation at 94 C for 45 s, annealing at 58 C for 45 s
Table 2 Genotype distribution and G allele frequency of
Q222R SNP in the DNAse I gene of rheumatoid arthritis
patients and control.
n (%) RA patients (n= 210) Control (n= 206) p
Q222R SNP 0.25
GG 87 (41.4) 93 (45.1)
AG 99 (47.1) 99 (48.1)
AA 24 (11.4) 14 (6.8)
G Allele 137 (65.2) 142 (68.9) 0.45
Table 3 Genotype distribution of Q222R SNP in the DNAse
I gene according to the disease activity, functional status and
radiological severity among the RA patients.







DAS28 <2.6 59.8 (52) 59.3 (73) 0.99
2.61–
3.2
11.5 (10) 12.2 (15)
>3.2 28.7 (25) 28.5 (35)
HAQ <1 63.0 (55) 56.7 (70) 0.53
1–2 25.9 (22) 33.3 (41)
>2 11.1 (10) 10.0 (12)
Modified
SvH
<58 25.2 (22) 24.7 (30) 0.99
58–119 24.4 (21) 25.9 (33)
120–
162
25.2 (22) 24.7 (30)
>162 25.2 (22) 24.7 (30)
DAS28: Disease Activity Score in 28 joints; HAQ: Health Assess-
ment Questionnaire, SvH: Sharp van de Heijde.
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72 C for 10 min. Fifteen microliters of the PCR product were
digested with 5 U of Sty I at 37 C for 4 h in a final reaction
mixture volume of 20 ll. The total digested product was sepa-
rated in a 2% agarose gel and visualized by staining with
SYBR Safe (Invitrogen, Eugene, OR, USA).
2.2. Statistical analysis
Statistical analysis was performed using SPSS statistical pack-
age (version 15.0 for window SPSS, Chicago, IL, USA).
Hardy–Weinberg equilibrium was tested for the studied poly-
morphisms using a Chi-squared test (v2). Because the data
are not normally distributed, they are presented as the medians
and percentiles (25 and 75) or percentages. Nonparametric
tests (U-Mann–Whitney) were used to compare quantitative
data, and the Chi square test or Fisher’s exact test was used
to compare proportions. A p< 0.05 was considered statisti-
cally significant (bold values).
3. Results
This study included 210 RA patients and 206 healthy controls
belonging to the Argentinean population. The socio-
demographic and clinical characteristics of patients with RA
included in the study are given in Table 1. The Q222R SNP
genotypes of the patients and control were concordant with
Hardy–Weinberg equilibrium (p> 0.05). Table 2 shows the
genotype distributions of the DNAse I Q222R SNP and the
corresponding allele frequencies in RA patients and controls.
As the G allele codes for an enzyme with reduced activity,
we analyzed its potential association with the risk of develop-
ing RA. No significant genetic association was found between
the carriage of the DNAse I Q222R G allele and the risk of RA
either under a dominant (OR = 0.56 [0.28–1.13]; p= 0.13) or
a recessive model (OR = 0.86 [0.58–1.27]; p= 0.49).
We also investigated the influence of the DNAse I Q222R
G allele on different clinical features among the RA patients
(Table 3). We did not find any significant association between
the carriage of the DNAse I Q222R GG genotype and theTable 1 Socio-demographic and clinical characteristics of
rheumatoid arthritis patients.
Variables RA patients (n= 210)
Gender female 182 (86.7)
Age (years) 56 (48–64)
Disease duration (months) 128 (20–205)
Positive Rheumatoid Factor 195 (92.9)
 Extra articular manifestations 134 (63.8)
 Subcutaneous nodules 47 (22.4)
 Fatigue 30 (14.3)
 Sicca syndrome 40 (19.04)
 Interstitial lung disease 86 (4.1)
 Vasculitis 38 (1.8)
DAS 28 2.27 (1.44–3.45)
HAQ 0.75 (0.25–1.5)
Modified SvH score 119 (58–162)
DAS28: Disease Activity Score in 28 joints; HAQ: Health Assess-
ment Questionnaire, SvH: Sharp van de Heijde. Data are expressed
as median with inter-quartile range or number (%).disease activity (DAS 28; p= 0.99), the functional capacity
(HAQ-A; p= 0.53), the severity of the disease (modified
SvH; p= 0.99) or any other recorded clinical feature.
4. Discussion
Since 2004, when evidence of a novel neutrophil-mediated
defense mechanism capable of generating extracellular DNA
traps was provided [22], many investigators have turned their
attention to this cell death program as a new way to explore
immunology. NETs are implicated in numerous pathological
conditions as thrombosis [23–25], cancer [26,27], atherosclero-
sis [28,29], sepsis [30,31], inflammation and autoimmunity dis-
eases [32]. Aberrant NET formation may play a central role
among the various mechanisms in the process by which neu-
trophils cause tissue damage and promote autoimmunity as
SLE or RA. In the presence of certain stimuli, some neutrophil
nuclei lose their characteristic lobular shape. Upon activation
and the production of reactive oxygen species, neutrophil
elastase translocates to the nucleus to cleave histones and pro-
mote chromatin decondensation. Subsequently, myeloperoxi-
dase translocates, binds to chromatin and promotes further
decondensation. Neutrophil elastase and myeloperoxidase
cooperatively enhance chromatin decondensation, leading to
cell rupture and NET release [33]. Furthermore, citrullination
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chromatin decondensation, driven by peptidylarginine deimi-
nase 4 (PADI4), an enzyme that enters the nucleus helping
to release NETs [34,35] and is a driving force in NETosis
[36]. Once NETs discharge their function, they have to be
removed from circulation, primarily by the action of the
DNAse I that dismantles the DNA fibers [37].
RA is a common autoimmune disease, characterized by
progressive disability, systemic complications, such as cardio-
vascular events, and early death. Many of the mechanisms
involved are not well established [38]. RA is characterized by
synovial inflammation and hyperplasia, autoantibody produc-
tion, cartilage and bone destruction [39]. Interactions between
the environment and genes promote loss of tolerance to self-
proteins that contain a citrullinated residue, which is generated
by post-translational modification. Some enzymes are func-
tionally associated with the production of RA-specific autoan-
tibodies as the aforementioned PADI4 [7,8]. In fact, some
authors identified haplotypes in PADI4 linked with suscepti-
bility to RA and with higher levels of antibodies to citrulli-
nated peptide in the appropriate HLA context [40,41]. More
recently, inhibition of PADI4 was shown to decrease genera-
tion of synovial citrulline, diminish antibody response to
citrullinated protein and other autoantigens, and substantially
reduce arthritis in a murine model [42]. However, there is little
information, if any, about the role of DNAse I in RA. It has
been shown that a subset of SLE patients display an impaired
DNase I-mediated NET degradation in their sera, mostly dur-
ing flares [37,43]. The defective NET degradation in SLE
tended to be correlated with higher levels of anti-NETs and
anti-dsDNA autoantibodies as well as with lupus nephritis
and lupus flares [37,44]. Certain DNAse I SNPs, mainly
Q222R, were associated with susceptibility to and/or course
of SLE disease in Spanish [13] and South Indian [14] popula-
tions. Yasuda et al. reported that Q222R substitution (A?
G) in the DNase I gene is associated with production of an
enzyme with reduced in vitro activity [11,45]. However, the
relationship of this SNP to other autoimmune diseases, includ-
ing RA, has not been studied elsewhere. Moreover, no Genetic
Wide Association Study has described any genetic variant that
might be associated with RA and that is in the same region or
even in the same chromosome than the DNAse I loci. Consid-
ering the above mentioned effects of NET defective degrada-
tion and that the Q222R G allele codes for a DNAse I with
a reduced activity, it could be hypothesized that the presence
of this allele could be associated with a reduced clearance of
NETs after its production by stimulated neutrophils. Thus,
the higher persistence of circulating NETs due to its impaired
degradation might be an important trigger in the beginning of
the RA pathophysiological process.
Therefore, we explored the association between Q222R
DNAse I SNP and RA in Argentine patients, but we did not
find any relationship with susceptibility to RA, the disease
activity, the functional capacity, the severity of the disease or
any other recorded clinical feature.
Besides this, it is worth mentioning that most of the RA
patients had long term of disease as well as low disease activity,
the functional ability was slightly impaired and, on the other
hand, they had high severity, according to the X-ray score.
Our RA group is composed by patients with long standing dis-
ease who were evaluated initially before the current paradigm
of RA treatment. That is the reason because these patientslacked the window of opportunity and had radiological dam-
age. However, these patients were actually followed up accord-
ing to a treat to target strategy and the disease activity was
under control.
In both, SLE and RA, NET appears to play an important
role, but in different ways. In SLE patients the main antibodies
are antinuclear antibodies, whereas the main antibodies in RA
patients are anti citrullinated peptide. PADI4 enzyme and cer-
tain SNPs play a significant role in RA, whereas DNAse I is
important among SLE patient. NETs generated in SLE and
RA have quite different molecular characteristic, and the host
responses to these NETs are quite different in the two diseases.
We could speculate that although SLE and RA are both
autoimmune diseases and thus may share a similar pathway
of etiology or even steps in progression, the trigger of the dis-
eases in genetically susceptible individuals would be different.
In conclusions, no significant genetic association was found
between the carriage of the DNAse I Q222R G-allele and the
risk of RA nor was there any association with the disease activ-
ity, functional capacity or severity in an Argentine patient
cohort. Identifying the role of NETosis and/or involved molecules
in RA pathogenesis could provide new targets for the treat-
ment of this disabling disease and its associated complications.Conflict of interest
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